ACRS vs GILD · rev $3.6M vs P/E 18, rev $7.80B
Aclaris Therapeutics Inc (ACRS) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ACRS currently screens at market cap $615.9M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ACRS and GILD stock pages for the full models.
Not investment advice.